BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50:123-128. [PMID: 11772979 DOI: 10.1136/gut.50.1.123] [Cited by in Crossref: 202] [Cited by in F6Publishing: 178] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Schwartz M. Liver transplantation: the preferred treatment for early hepatocellular carcinoma in the setting of cirrhosis? Ann Surg Oncol 2007;14:548-52. [PMID: 17009143 DOI: 10.1245/s10434-006-9157-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
2 Royston C, Caygill C, Charlett A, Bardhan KD. The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital. Eur J Gastroenterol Hepatol 2016;28:1365-73. [PMID: 27571366 DOI: 10.1097/MEG.0000000000000730] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
4 Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for HCC. Ann Surg Oncol. 2008;15:993-1000. [PMID: 18236111 DOI: 10.1245/s10434-007-9787-8] [Cited by in Crossref: 82] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
5 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 van Blankenstein M, Böhmer CJ, Hop WC. The incidence of adenocarcinoma in Barrett's esophagus in an institutionalized population. Eur J Gastroenterol Hepatol 2004;16:903-9. [PMID: 15316416 DOI: 10.1097/00042737-200409000-00015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tognolini A, Louie JD, Hwang GL, Hofmann LV, Sze DY, Kothary N. Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2010;21:339-347. [PMID: 20133156 DOI: 10.1016/j.jvir.2009.11.007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
8 Cohen EI, Field D, Lynskey GE, Kim AY. Technology of irreversible electroporation and review of its clinical data on liver cancers. Expert Rev Med Devices 2018;15:99-106. [PMID: 29307242 DOI: 10.1080/17434440.2018.1425612] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Díaz-Sánchez A, Matilla A, Núñez O, Merino B, Peligros I, Rincón D, Salcedo M, Lo Iacono O, Vega Catalina M, Clemente G, Bañares R. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival]. Gastroenterol Hepatol 2010;33:155-64. [PMID: 19945770 DOI: 10.1016/j.gastrohep.2009.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Branco F, Brú C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Annals of Hepatology 2009;8:220-7. [DOI: 10.1016/s1665-2681(19)31769-7] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
11 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 6.8] [Reference Citation Analysis]
12 Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol. 2012;24:186-194. [PMID: 22081008 DOI: 10.1097/meg.0b013e32834dda64] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
13 Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, González García P, Antón De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ 2012;13:723-40. [PMID: 21660565 DOI: 10.1007/s10198-011-0326-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
14 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 753] [Article Influence: 40.1] [Reference Citation Analysis]
15 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. The Lancet Oncology 2004;5:409-18. [DOI: 10.1016/s1470-2045(04)01508-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
16 Saverio Ferrari F, Stella A, Pasquinucci P, Vigni F, Civeli L, Pieraccini M, Magnolfi F. Treatment of small hepatocellular carcinoma: a comparison of techniques and long-term results: . European Journal of Gastroenterology & Hepatology 2006;18:659-72. [DOI: 10.1097/00042737-200606000-00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
17 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
18 Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl. 2007;13:S36-S43. [PMID: 17969067 DOI: 10.1002/lt.21329] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
19 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
20 Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5987-5998 [PMID: 24876721 DOI: 10.3748/wjg.v20.i20.5987] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
21 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
22 Cheng H, Liu YF, Zhang HZ, Shen WA, Zhang J, Zhang J. In vivo antitumour activity of PBMCs via genetic modification of single-chain immunotoxin. Shijie Huaren Xiaohua Zazhi 2003; 11(6): 708-711 [DOI: 10.11569/wcjd.v11.i6.708] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Bock JA, Fairley KJ, Smith RE, Maeng DD, Pitcavage JM, Inverso NA, Williams MS. Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 2014;17:306-19. [PMID: 25247313 DOI: 10.1159/000365939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007;13:857-66. [DOI: 10.1002/lt.21155] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
25 Lambert B, Praet M, Vanlangenhove P, Troisi R, de Hemptinne B, Gemmel F, Van Vlierberghe H, Van de Wiele C. Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome. Cancer Biother Radiopharm. 2005;20:209-214. [PMID: 15869457 DOI: 10.1089/cbr.2005.20.209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
26 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
27 Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012;105:692-698. [PMID: 21960321 DOI: 10.1002/jso.22104] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
28 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
29 Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900-909. [PMID: 15492574 DOI: 10.1097/01.sla.0000143301.56154.95] [Cited by in Crossref: 356] [Cited by in F6Publishing: 319] [Article Influence: 19.8] [Reference Citation Analysis]
30 Alba E, Valls C, Dominguez J, Martinez L, Escalante E, Lladó L, Serrano T. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol. 2008;190:1341-1348. [PMID: 18430853 DOI: 10.2214/ajr.07.2972] [Cited by in Crossref: 50] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
31 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
32 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
33 García-Criado A, Gilabert R, Bargalló X, Brú C. Radiology in liver transplantation. Semin Ultrasound CT MR. 2002;23:114-129. [PMID: 11866218 DOI: 10.1016/s0887-2171(02)90032-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
34 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
35 Almeida J, Mesquita M, Ferraz J, Yamanaka A, Escanhoela C, Boin IF, Pereira G, Pereira T, Soares E. Hepatocellular carcinoma developing at the puncture site after percutaneous ethanol injection. J Clin Ultrasound 2008;36:105-7. [DOI: 10.1002/jcu.20428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003;7:683-714. [PMID: 14509534 DOI: 10.1016/s1089-3261(03)00060-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
37 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
38 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 2015;12:481-9. [PMID: 25985939 DOI: 10.1038/nrclinonc.2015.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
39 Cheng H, Liu YF, Zhang HZ, Shen WA, Zhang J, Zhang J. In vitro cytotoxicity of PBMCs via genetic modification of single-chain immunotoxin. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 281-284 [DOI: 10.11569/wcjd.v11.i3.281] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
41 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
42 Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P, Klein KM, Chun H, Marvin M, Rozenblit G. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol. 2008;15:1383-1391. [PMID: 18320284 DOI: 10.1245/s10434-008-9851-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
43 Castroagudin J, Delgado M, Martinez S, Abdulkader I, Potel J, Tome S, Otero E, Varo E. Prospective Histopathological Analysis of Hepatocellular Carcinoma Treated With Percutaneous Ethanol Injection in Patients on the Waiting List for Liver Transplantation. Transplantation Proceedings 2005;37:1477-9. [DOI: 10.1016/j.transproceed.2005.02.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
44 Schwartz M, Lopez P. Waiting List Treatment of Hepatocellular Carcinoma: When Do We Need Level 1 Evidence? Am J Transplant 2006;6:2531-2. [DOI: 10.1111/j.1600-6143.2006.01572.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 2011;13:783-91. [PMID: 21999591 DOI: 10.1111/j.1477-2574.2011.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
46 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 292] [Article Influence: 55.7] [Reference Citation Analysis]
47 Kim HY, Kim W, Jung YJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HW, Kim H, Yi NJ, Lee KW, Suh KS. A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. J Clin Gastroenterol 2018;52:655-61. [PMID: 29356782 DOI: 10.1097/MCG.0000000000000981] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant. 2008;22:469-475. [PMID: 18318736 DOI: 10.1111/j.1399-0012.2008.00811.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
49 Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl. 2014;20:528-535. [PMID: 24415542 DOI: 10.1002/lt.23820] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
50 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Gastroenterología y Hepatología 2015;38:600-18. [DOI: 10.1016/j.gastrohep.2015.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
52 Sherman M, Takayama Y. Screening and treatment for hepatocellular carcinoma. Gastroenterology Clinics of North America 2004;33:671-91. [DOI: 10.1016/j.gtc.2004.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
53 Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol. 2012;39:510-521. [PMID: 22846868 DOI: 10.1053/j.seminoncol.2012.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
54 Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl. 2011;17 Suppl 2:S98-108. [PMID: 21954097 DOI: 10.1002/lt.22391] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
55 Nazzal M, Gadani S, Said A, Rice M, Okoye O, Taha A, Lentine K. Liver targeted therapies for hepatocellular carcinoma prior to transplant: contemporary management strategies. Glob Surg 2017;3. [DOI: 10.15761/gos.1000171] [Reference Citation Analysis]
56 McLennan G, Cressman EN, Xu Y, Zhang D, Jagtap MR, Jayaram HN. The effect of benzamide riboside on the VX2 model of liver cancer in rabbits. J Vasc Interv Radiol 2005;16:1499-504. [PMID: 16319157 DOI: 10.1097/01.RVI.0000185416.08458.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg 2003;90:1379-83. [PMID: 14598418 DOI: 10.1002/bjs.4271] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
58 Belghiti J, Durand F. Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome? Liver Int. 2011;31 Suppl 1:161-163. [PMID: 21205155 DOI: 10.1111/j.1478-3231.2010.02413.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ 2nd. A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. Pharmacoecon Open 2021. [PMID: 34427897 DOI: 10.1007/s41669-021-00298-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Freeman RB. Liver allocation for HCC: A moving target. Liver Transpl 2004;10:49-51. [DOI: 10.1002/lt.20027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
61 Molmenti EP, Klein AS. Liver transplantation for hepatocellular carcinoma: . Current Opinion in Organ Transplantation 2002;7:124-8. [DOI: 10.1097/00075200-200206000-00003] [Reference Citation Analysis]
62 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
63 Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18:1517-1526; quiz 1527. [PMID: 18057286 DOI: 10.1016/j.jvir.2007.07.035] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 4.5] [Reference Citation Analysis]
64 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
65 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Bolondi L, Piscaglia F, Camaggi V, Grazi GL, Cavallari A. Review article: liver transplantation for HCC. Treatment options on the waiting list. Aliment Pharmacol Ther. 2003;17 Suppl 2:145-150. [PMID: 12786626 DOI: 10.1046/j.1365-2036.17.s2.8.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
67 Majno P, Mentha G, Toso C; for the Geneva Liver Cancer Study Group. Transplantation for hepatocellular carcinoma: Management of patients on the waiting list. Liver Transpl 2010;16:S2-S11. [DOI: 10.1002/lt.22163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P, Schmidt J, Büchler MW, Schemmer P. Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transplant 2011;25:E541-51. [PMID: 21518002 DOI: 10.1111/j.1399-0012.2011.01465.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
69 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
70 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
71 Kim PTW, Onaca N, Chinnakotla S, Davis GL, Jennings LW, Mckenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013;27:311-8. [DOI: 10.1111/ctr.12089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
72 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
73 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
74 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
75 Lerut J. Carcinome hépatocellulaire et transplantation hépatique : état des lieux. Journal de Chirurgie 2007;144:105-10. [DOI: 10.1016/s0021-7697(07)89481-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
77 Agrawal S, Dhiman RK. Hepatobiliary quiz-12 (2014). J Clin Exp Hepatol 2014;4:376-9. [PMID: 25755586 DOI: 10.1016/j.jceh.2014.11.004] [Reference Citation Analysis]
78 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
79 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
80 Stippel D, Kasper H, Schleimer K, Benz C, Hölscher A, Beckurts K. Underestimation of nodules while staging hepatocellular carcinoma prior to neoadjuvant treatment on waiting list for transplantation. Transplantation Proceedings 2003;35:1423-4. [DOI: 10.1016/s0041-1345(03)00456-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant. 2006;6:1416-1421. [PMID: 16686765 DOI: 10.1111/j.1600-6143.2006.01321.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 134] [Article Influence: 9.3] [Reference Citation Analysis]
82 Facciuto ME, Singh MK, Katta U, Samaniego S, Sharma J, Rodriguez-davalos M, Sheiner P, Kim-schluger L, Wolf DC. Liver Transplantation for Hepatocellular Carcinoma: Defining the Impact of Using Extended Criteria Liver Allografts. Transplantation 2011;92:446-52. [DOI: 10.1097/tp.0b013e3182252733] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
83 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
84 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
85 Blum M, Mueller C, Peck‐radosavljevic M, Wrba F, Berlakovich G, Mühlbacher F, Steiniger R, Speiser M, Pones M, Hüpfl M, Lammer J, Kettenbach J. MR‐guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. Minimally Invasive Therapy & Allied Technologies 2009;16:230-40. [DOI: 10.1080/13645700701520677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
86 Turri JAO, Decimoni TC, Ferreira LA, Diniz MA, Haddad LBDP, Campolina AG. Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study. Arq Gastroenterol 2017;54:238-45. [DOI: 10.1590/s0004-2803.201700000-35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
87 Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;80:S113-S119. [PMID: 16286887 DOI: 10.1097/01.tp.0000187109.69663.93] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
88 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
89 Majno P, Giostra E, Morel P, Hadengue A, Mentha G. Management of hepatocellular carcinoma in the waiting list before liver transplantation. Journal of Hepatology 2005;42:S134-43. [DOI: 10.1016/j.jhep.2004.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
90 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
91 Adam R, Del Gaudio M. Evolution of liver transplantation for hepatocellular carcinoma. J Hepatol. 2003;39:888-895. [PMID: 14642602 DOI: 10.1016/j.jhep.2003.10.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
92 Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
93 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
94 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
95 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
96 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
97 Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174. [PMID: 12474157 DOI: 10.1053/jlts.2002.36394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.2] [Reference Citation Analysis]
98 Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795-804. [PMID: 15760404 DOI: 10.1111/j.1600-6143.2005.00750.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 121] [Article Influence: 8.2] [Reference Citation Analysis]
99 Lu SY, Sui YF, Li ZS, Pan CE, Ye J, Wang WY. Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma. World J Gastroenterol 2003; 9(4): 688-691 [PMID: 12679911 DOI: 10.3748/wjg.v9.i4.688] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
100 Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, Afdhal NH. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer 2016;122:852-8. [PMID: 26716758 DOI: 10.1002/cncr.29855] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
101 Torzilli G, Belghiti J, Makuuchi M. Differences and similarities in the approach to hepatocellular carcinoma between Eastern and Western institutions. Liver Transpl 2004;10:S1-2. [PMID: 14762830 DOI: 10.1002/lt.20032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
103 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
104 Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB. LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol 2018;43:193-202. [DOI: 10.1007/s00261-017-1210-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
105 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 131] [Article Influence: 3.5] [Reference Citation Analysis]
106 Dageforde LA, Feurer ID, Pinson CW, Moore DE. Is liver transplantation using organs donated after cardiac death cost-effective or does it decrease waitlist death by increasing recipient death? HPB (Oxford) 2013;15:182-9. [PMID: 23374358 DOI: 10.1111/j.1477-2574.2012.00524.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
107 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
108 Terzi E, Ray Kim W, Sanchez W, Charlton MR, Schmeltzer P, Gores GJ, Andrews JC, Smyrk TC, Heimbach JK. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation: MULTIPLE TACE PROCEDURES. Liver Transpl 2015;21:248-57. [DOI: 10.1002/lt.24041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
109 Lerut J, Julliard O, Ciccarelli O, Lannoy V, Gofette P. Hepatocellular cancer and liver transplantation: a Western experience. Recent Results Cancer Res 2013;190:127-44. [PMID: 22941018 DOI: 10.1007/978-3-642-16037-0_9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. [PMID: 14762851 DOI: 10.1002/lt.20034] [Cited by in Crossref: 459] [Cited by in F6Publishing: 424] [Article Influence: 25.5] [Reference Citation Analysis]
111 Stone MJ, Fulmer JM, Klintmalm GB. Transplantation for Primary Hepatic Malignancy. Transplantation of the Liver. Elsevier; 2005. pp. 211-31. [DOI: 10.1016/b978-0-7216-0118-2.50020-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther. 2003;17 Suppl 2:130-137. [PMID: 12786624 DOI: 10.1046/j.1365-2036.17.s2.16.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
113 Li K, Neuberger J. The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol 2009;6:648-59. [DOI: 10.1038/nrgastro.2009.163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Satiya J, Schwartz I, Tabibian JH, Kumar V, Girotra M. Ablative therapies for hepatic and biliary tumors: endohepatology coming of age. Transl Gastroenterol Hepatol 2020;5:15. [PMID: 32258519 DOI: 10.21037/tgh.2019.10.17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
115 Northup PG, Abecassis MM, Englesbe MJ, Emond JC, Lee VD, Stukenborg GJ, Tong L, Berg CL; Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost. Liver Transpl 2009;15:148-62. [PMID: 19177435 DOI: 10.1002/lt.21671] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
116 Kakodkar R, Soin AS. Liver Transplantation for HCC: A Review. Indian J Surg. 2012;74:100-117. [PMID: 23372314 DOI: 10.1007/s12262-011-0387-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
117 Cha C. Surgical Therapy for Hepatocellular Carcinoma: Formulating a Rational Approach. Journal of Clinical Gastroenterology 2013;47:S30-6. [DOI: 10.1097/mcg.0b013e31829440bd] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
118 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
119 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
120 Brown R, Emond JC. Managing Access to Liver Transplantation: Implications for Gastroenterology Practice. Gastroenterology 2007;132:1152-63. [DOI: 10.1053/j.gastro.2007.01.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
122 Costanzo GGD, Francica G, Pacella CM. Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives. World J Hepatol 2014; 6(10): 704-715 [PMID: 25349642 DOI: 10.4254/wjh.v6.i10.704] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
123 Fuster J, Charco R, Llovet JM, Bruix J, García-Valdecasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005;18:278-282. [PMID: 15730486 DOI: 10.1111/j.1432-2277.2004.00046.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
124 Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: Time for controlled trials? Liver Transpl 2007;13:S27-35. [DOI: 10.1002/lt.21328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
125 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
126 Shinozawa T, Yoshikawa HY, Takebe T. Reverse engineering liver buds through self-driven condensation and organization towards medical application. Dev Biol 2016;420:221-9. [PMID: 27364470 DOI: 10.1016/j.ydbio.2016.06.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
127 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
128 Castroagudín JF, Delgado M, Villanueva A, Bustamante M, Martínez J, Otero E, Tomé S, Martínez SM, Segade FR, Conde R. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc. 2005;37:3871-3873. [PMID: 16386568 DOI: 10.1016/j.transproceed.2005.09.168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
129 Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol 2015;62:1076-84. [PMID: 25529626 DOI: 10.1016/j.jhep.2014.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
130 Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010;51:165-73. [DOI: 10.1002/hep.23260] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
131 Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, Durand F, Belghiti J, Sommacale D, Vilgrain V. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006;186:S296-S305. [PMID: 16632691 DOI: 10.2214/ajr.04.1927] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
132 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
133 Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-14. [PMID: 16315294 DOI: 10.1002/lt.20526] [Cited by in Crossref: 209] [Cited by in F6Publishing: 191] [Article Influence: 13.1] [Reference Citation Analysis]
134 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 21.1] [Reference Citation Analysis]
136 Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-9. [PMID: 15860847 DOI: 10.1200/JCO.2005.03.196] [Cited by in Crossref: 278] [Cited by in F6Publishing: 136] [Article Influence: 16.4] [Reference Citation Analysis]
137 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
138 Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB, Hertl M. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011;46:249-56. [PMID: 20711612 DOI: 10.1007/s00535-010-0302-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
139 Valverde-lópez F, Angeles López Garrido M, Ortega-suazo E, Vadillo-calles F, Muffak-granero K, Nogueras-lópez F. Results of 15-Year Experience in Liver Transplant for Hepatocellular Carcinoma. Transplantation Proceedings 2018;50:617-8. [DOI: 10.1016/j.transproceed.2017.11.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Gough-Palmer AL, Gedroyc WMW. Laser ablation of hepatocellular carcinoma-A review. World J Gastroenterol 2008; 14(47): 7170-7174 [PMID: 19084930 DOI: 10.3748/wjg.14.7170] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
141 Sala M, Varela M, Bruix J. Selection of candidates with HCC for transplantation in the MELD era. Liver Transpl. 2004;10:S4-S9. [PMID: 15382217 DOI: 10.1002/lt.20263] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
142 Geschwind JF. Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol. 2002;13:991-994. [PMID: 12397119 DOI: 10.1016/s1051-0443(07)61862-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
143 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 9.9] [Reference Citation Analysis]
144 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
145 Végső G, Görög D, Fehérvári I, Nemes B, Doros A, Langer RM, Kóbori L. Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation. Pathol Oncol Res 2012;18:1-10. [DOI: 10.1007/s12253-011-9441-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
146 Freeman RB, Harper A, Edwards EB. Liver transplantation outcomes under the model for end-stage liver disease and pediatric end-stage liver disease: . Current Opinion in Organ Transplantation 2005;10:90-4. [DOI: 10.1097/01.mot.0000161760.02748.ce] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
147 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
148 Masuoka HC, Rosen CB. Liver Transplantation for Hepatocellular Carcinoma: Expanding Frontiers and Building Bridges. Clinics in Liver Disease 2011;15:385-93. [DOI: 10.1016/j.cld.2011.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
149 Marin D, Cappabianca S, Serra N, Sica A, Lassandro F, D'Angelo R, La Porta M, Fiore F, Somma F. CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterol Res Pract 2015;2015:670965. [PMID: 26798332 DOI: 10.1155/2015/670965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
150 Kim HD, Song GW, Shim JH, Han S, An J, Moon DB, Kim KM, Lim YS, Ko GY, Hwang S, Lee HC, Yu E, Sung KB, Lee SG. Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma. Hepatol Int 2017;11:209-19. [PMID: 28144812 DOI: 10.1007/s12072-017-9785-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
151 Gores G. Hepatocellular carcinoma: Gardening strategies and bridges to transplantation. Liver Transplantation 2003;9:199-200. [DOI: 10.1053/jlts.2003.0090199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
152 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
153 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
154 Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, Mehrabi A, Fonouni H, Bechstein WO, Golling M. Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis. Clin Transplant 2009;23 Suppl 21:61-7. [PMID: 19930318 DOI: 10.1111/j.1399-0012.2009.01111.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
155 Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90:803-816. [PMID: 20637949 DOI: 10.1016/j.suc.2010.04.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
156 Xu L, Chen L, Zhang W. Neoadjuvant treatment strategies for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(12): 1550-1566 [DOI: 10.4240/wjgs.v13.i12.1550] [Reference Citation Analysis]
157 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 212] [Article Influence: 21.0] [Reference Citation Analysis]
158 Chern MC, Chuang VP, Liang CT, Lin ZH, Kuo TM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors. J Vasc Interv Radiol. 2014;25:32-40. [PMID: 24290099 DOI: 10.1016/j.jvir.2013.10.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
159 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Cirugía Española 2015;93:619-37. [DOI: 10.1016/j.ciresp.2015.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
160 Andriulli A, de Sio I, Solmi L, De Carlis L, Troisi R, Grasso A, Festa V, Caturelli E, Giacomoni A, Del Vecchio Blanco C, De Hemptinne B, Burroughs A, Perri F. Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation. Liver Transpl 2004;10:1355-63. [DOI: 10.1002/lt.20251] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
161 Freeman RB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl. 2006;12:S8-13. [PMID: 17051567 DOI: 10.1002/lt.20936] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
162 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
163 Morisco F, Stigliano R, Godfrey A, Leandro G, Patch D, Davidson B, Rolles K, Dhillon A, Dhillon AP, Quaglia A. Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. Dig Dis Sci. 2008;53:1131-1137. [PMID: 17934816 DOI: 10.1007/s10620-007-9986-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
164 McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford). 2010;12:56-61. [PMID: 20495646 DOI: 10.1111/j.1477-2574.2009.00128.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 5.6] [Reference Citation Analysis]
165 Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013;33:944-949. [PMID: 23530918 DOI: 10.1111/liv.12144] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
166 Guo C, Zou X, Hong Z, Sun J, Xiao W, Sun K, Li X, Shen Y, Liang T, Bai X. Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. HPB (Oxford) 2021:S1365-182X(21)00043-5. [PMID: 33715958 DOI: 10.1016/j.hpb.2021.02.006] [Reference Citation Analysis]
167 Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883. [PMID: 12360427 DOI: 10.1053/jlts.2002.34923] [Cited by in Crossref: 291] [Cited by in F6Publishing: 279] [Article Influence: 15.3] [Reference Citation Analysis]
168 Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, Shaked A, Furth E, Reddy KR, Olthoff K. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 2006;12:665-673. [PMID: 16482577 DOI: 10.1002/lt.20636] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 6.5] [Reference Citation Analysis]
169 Tan CHN, Yu Y, Tan YRN, Lim BLK, Iyer SG, Madhavan K, Kow AWC. Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? Ann Hepatobiliary Pancreat Surg 2018;22:27-35. [PMID: 29536053 DOI: 10.14701/ahbps.2018.22.1.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
170 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol 2013; 5(7): 364-371 [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
171 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
172 Brennan IM, Ahmed M. Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. Semin Ultrasound CT MR. 2013;34:336-351. [PMID: 23895906 DOI: 10.1053/j.sult.2013.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
173 Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant. 2007;7:1875-1881. [PMID: 17532747 DOI: 10.1111/j.1600-6143.2007.01863.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
174 Delicque J, Boulin M, Guiu B, Pelage J, Escal L, Schembri V, Assenat E, Fohlen A. Interventional oncology for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:530-7. [DOI: 10.1016/j.clinre.2016.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
175 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
176 Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127:S261-S267. [PMID: 15508092 DOI: 10.1053/j.gastro.2004.09.040] [Cited by in Crossref: 208] [Cited by in F6Publishing: 174] [Article Influence: 11.6] [Reference Citation Analysis]
177 Silva M, Mattos AA, Fontes PR, Waechter FL, Pereira-Lima L. [Evaluation of hepatic resection for hepatocellular carcinoma on cirrhotic livers]. Arq Gastroenterol 2008;45:99-105. [PMID: 18622461 DOI: 10.1590/s0004-28032008000200002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
179 Kim YS. Percutaneous interventional procedures in an era of liver transplantation. Korean J Hepatol 2011;17:96-8. [PMID: 21757979 DOI: 10.3350/kjhep.2011.17.2.96] [Reference Citation Analysis]
180 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
181 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
182 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
183 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
184 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
185 Ravaioli M, Grazi GL, Ercolani G, Fiorentino M, Cescon M, Golfieri R, Trevisani F, Grigioni WF, Bolondi L, Pinna AD. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation. 2004;78:1780-1786. [PMID: 15614151 DOI: 10.1097/01.tp.0000145892.97114.ee] [Cited by in Crossref: 92] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
186 Tan EK, Goh BKP, Lee SY, Krishnamoorthy TL, Tan CK, Jeyaraj PR. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center. Transplant Proc 2018;50:3564-70. [PMID: 30577239 DOI: 10.1016/j.transproceed.2018.08.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Sá GPD, Carlotto JRM, Vicentine FPP, Romero L, Tejada DFP, Salzedas AA Netto, Lopes GJ Filho, Gonzalez AM. Evaluation of the treatment of the hepatocarcinoma nodules in the patients in waiting list for liver transplant. Rev Col Bras Cir 2017;44:360-6. [PMID: 29019539 DOI: 10.1590/0100-69912017004010] [Reference Citation Analysis]
188 Lo C, Fan S. Liver transplantation for hepatocellular carcinoma. British Journal of Surgery 2004;91:131-3. [DOI: 10.1002/bjs.4503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]